Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. OXiGENE, The Vascular Targeting Company, was originally incorporated in New York in 1988 and reincorporated in Delaware in 1992. OXiGENE is a biopharmaceutical company engaged principally in research into and the development of products for use in the treatment of cancer. Historically, the company's activities were directed primarily towards products designed to complement and enhance the clinical efficacy of radiation and chemotherapy. In 2000, OXiGENE announced its intent to focus exclusively on advancing and developing its vascular targeting agents (VTAs). The company is also investigating the use of certain products for other applications in the field of ophthalmology, in particular age-related macular degeneration and diabetic retinopathy.